Literature DB >> 22124806

Quantitation of multiple sphingolipid classes using normal and reversed-phase LC-ESI-MS/MS: comparative profiling of two cell lines.

M Athar Masood1, Raghavendra P Rao, Jairaj K Acharya, Josip Blonder, Timothy D Veenstra.   

Abstract

Sphingolipids are an important class of compounds that regulate signal transduction and other vital cellular processes. Herein, we report sensitive normal and reversed phase LC-MS/MS methods for quantitation of multiple sphingolipid classes. In the normal-phase ESI/MS/MS method, a high content of organic solvents was utilized, which, although it included hexane, ethyl acetate, acetonitrile containing 2% methanol, 1-2% acetic acid, and 5 mM ammonium acetate, resulted in a very efficient electrospray ionization of the ceramides (Cers) and hexosylceramides (MHCers). Three normal-phase LC-MS/MS methods using segmented phases were developed to specifically target Cers, MHCers, or sphingomyelins (SMs). This segmentation scheme increases the number of data points acquired for a given analyte and enhances the sensitivity and specificity of the measurements. Nine separate reversed phase chromatography methods were developed for the three classes of compounds. These assays were used for comparing the levels of Cers, SMs, and MHCers from mouse embryonic fibroblast (pMEF) and human embryonic kidney (HEK293) cells. These findings were then compared with the reported data from RAW264.7 mouse macrophage cells, BHK21 hamster cells, and human plasma and serum samples. The analysis of cell lines, using both normal and reversed phase chromatography, revealed discrimination based on the type of chromatography chosen, while sphingolipid assays of samples containing different amounts of protein showed different results, even after normalizing for protein content. Also, LC/MS/MS profiles were provided for the classes and individual compounds so that they could be used as "molecular profiles" for class or individual sample analysis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22124806      PMCID: PMC7480952          DOI: 10.1007/s11745-011-3633-2

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  48 in total

1.  Modulating sphingolipid biosynthetic pathway rescues photoreceptor degeneration.

Authors:  Usha Acharya; Shetal Patel; Edmund Koundakjian; Kunio Nagashima; Xianlin Han; Jairaj K Acharya
Journal:  Science       Date:  2003-03-14       Impact factor: 47.728

2.  Analysis of sphingomyelin, glucosylceramide, ceramide, sphingosine, and sphingosine 1-phosphate by tandem mass spectrometry.

Authors:  M C Sullards
Journal:  Methods Enzymol       Date:  2000       Impact factor: 1.600

3.  Fatty acid synthase overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.

Authors:  Shuji Ogino; Takako Kawasaki; Akiyo Ogawa; Gregory J Kirkner; Massimo Loda; Charles S Fuchs
Journal:  Hum Pathol       Date:  2007-03-12       Impact factor: 3.466

4.  Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry.

Authors:  Alfred H Merrill; M Cameron Sullards; Jeremy C Allegood; Samuel Kelly; Elaine Wang
Journal:  Methods       Date:  2005-06       Impact factor: 3.608

5.  Characterization and direct quantitation of ceramide molecular species from lipid extracts of biological samples by electrospray ionization tandem mass spectrometry.

Authors:  Xianlin Han
Journal:  Anal Biochem       Date:  2002-03-15       Impact factor: 3.365

6.  Structure-specific, quantitative methods for analysis of sphingolipids by liquid chromatography-tandem mass spectrometry: "inside-out" sphingolipidomics.

Authors:  M Cameron Sullards; Jeremy C Allegood; Samuel Kelly; Elaine Wang; Christopher A Haynes; Hyejung Park; Yanfeng Chen; Alfred H Merrill
Journal:  Methods Enzymol       Date:  2007       Impact factor: 1.600

7.  Characterization of overall ceramide species in human stratum corneum.

Authors:  Yoshinori Masukawa; Hirofumi Narita; Eri Shimizu; Naoki Kondo; Yoshiya Sugai; Tsuyoshi Oba; Rika Homma; Junko Ishikawa; Yutaka Takagi; Takashi Kitahara; Yoshinori Takema; Katsumi Kita
Journal:  J Lipid Res       Date:  2008-03-23       Impact factor: 5.922

Review 8.  Molecular facets of sphingolipids: mediators of diseases.

Authors:  Fatma Betul Kavun Ozbayraktar; Kutlu O Ulgen
Journal:  Biotechnol J       Date:  2009-07       Impact factor: 4.677

Review 9.  Lipid signalling in disease.

Authors:  Matthias P Wymann; Roger Schneiter
Journal:  Nat Rev Mol Cell Biol       Date:  2008-02       Impact factor: 94.444

10.  Quantitative analysis of sphingolipids for lipidomics using triple quadrupole and quadrupole linear ion trap mass spectrometers.

Authors:  Rebecca L Shaner; Jeremy C Allegood; Hyejung Park; Elaine Wang; Samuel Kelly; Christopher A Haynes; M Cameron Sullards; Alfred H Merrill
Journal:  J Lipid Res       Date:  2008-11-25       Impact factor: 5.922

View more
  3 in total

1.  Comparative Analysis of Biological Sphingolipids with Glycerophospholipids and Diacylglycerol by LC-MS/MS.

Authors:  Hideo Ogiso; Makoto Taniguchi; Shinichi Araya; Shinya Aoki; Lusi Oka Wardhani; Yuka Yamashita; Yoshibumi Ueda; Toshiro Okazaki
Journal:  Metabolites       Date:  2014-01-27

2.  Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets β-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Δ4-desaturase 1.

Authors:  Eugenia Poliakov; William Samuel; Todd Duncan; Danielle B Gutierrez; Nathan L Mata; T Michael Redmond
Journal:  PLoS One       Date:  2017-04-27       Impact factor: 3.240

Review 3.  Sphingolipids in Obesity and Correlated Co-Morbidities: The Contribution of Gender, Age and Environment.

Authors:  Enrica Torretta; Pietro Barbacini; Nasser M Al-Daghri; Cecilia Gelfi
Journal:  Int J Mol Sci       Date:  2019-11-24       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.